Dr. Gerald (Jerry) Nepom, who founded BRI’s Diabetes Research Program in the 1980’s, and who led BRI’s growth as a world-class research institute for 3 decades, now devotes his time to a laser-focused effort on getting experimental therapies to patients. As the leader of the Immune Tolerance Network—an international organization of scientific and clinical experts in immunological diseases—Jerry directs teams of investigators who design, conduct, and analyze clinical trials for type 1 diabetes, as well as other autoimmune diseases and organ transplantation. We asked Jerry to answer a few questions about the state of T1D research:
